Abstract:Background: Brain metastases (BM) represent one of the most common challenges related to non-small cell lung cancer (NSCLC), with evolving treatment strategies. We have conducted a phase II clinical trial in a Chinese population to evaluate concomitant treatment with whole brain radiotherapy (WBRT) and Gefitinib in patients with BM from NSCLC. The purpose of this study is to report the efficacy and toxicity of this treatment, and assess its impact on patient Quality of Life (QoL) and survival post-treatment.Patients and methods: Between October 2005 and January 2007, 21 patients were enrolled and received 40 Gy/20f/4w WBRT. Gefitinib was administrated orally at a dosage of 250 mg/day during the radiation course and was continued for each 28-day treatment cycle until progression of the disease, unacceptable toxicity, or withdrawal of consent. The primary end point of the study was tumor response and QoL The secondary end points were toxicity and survival. Objective response rate according to the RECIST criteria was recorded. Health-related QoL was measured using FACT-Br (V4.0) and toxicity was evaluated and recorded using the NCI Common Toxicity Criteria. The Kaplan-Meier method was used to evaluate patient survival. Univariate analysis of patient characteristics and tumor responses was conducted using the Chi-square and Fisher's exact test.Results: Four (19%) and 13 patients (62%) had a complete and partial response respectively, while 3 patients disease remained stable and I patient had progression of the disease. The overall response rate (81%, 95% confidence interval (Cl): 58-95%) exceeded the goal per study design. The median progression-free survival and overall survival were 10.0 months (95% Cl: 7.5-12.5 months)and 13.0 months (95% Cl: 8.2-17.8 months), respectively. The most frequent toxicities included rash (86%) and diarrhea (43%), with only 3 patients developing a grade III diarrhea. Other grade H or higher toxicities occurring in about 50% of patients included nausea, vomiting, headache, and fatigue. Most side effects were grade II and well tolerated by supportive care. Gender and cigarettes/year were predictive factors for the responses found in univariate analysis. All domains of QoL were significantly improved following treatment.Conclusion: Our data suggests that concomitant treatment was well tolerated, with promising activity and a significant improvement of QoL in a Chinese population with brain metastases from NSCLC. Although the data presented herewithin appears promising, more data from randomized trials are needed to further validate this regimen of WBRT/Gefitinib. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

EP12.01-40 the Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Whole-Brain Radiotherapy Combined with Anlotinib for Multiple Brain Metastases from Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Whole-brain Radiotherapy with and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a Multicenter, Open-Label, Randomized, Controlled Phase III Trial

The Theoretical Foundation and Research Progress for Erlotinib Combined with Whole Brain Radiotherapy for the Treatment for Non-Small Cell Lung Cancer Patients with Brain Metastases

Phase Ii Study of Whole Brain Radiotherapy with or Without Erlotinib in Patients with Multiple Brain Metastases from Lung Adenocarcinoma

Efficacy and safety of EGFR-TKI combined with WBRT vs. WBRT alone in the treatment of brain metastases from NSCLC: a systematic review and meta-analysis

A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases

Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor

Cmar_a_196881 3433..3443

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis

Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib in a Chinese Population.

Treatment Preferences for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer with Brain Metastasis: a Large-Scale Survey from Chinese Oncologists.

The Theoretical Foundation And Research Progress For Wbrt Combined With Erlotinib For The Treatment Of Multiple Brain Metastases In Patients With Lung Adenocarcinoma

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

Treatment for Brain Metastases from EGFR Mutations NSCLC Patients:How Should We Choose in Clinical Practice?

Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT

Optimal Treatment Strategy of Radiotherapy and Crizotinib for Patients with Brain Metastasis from ALK-Rearranged Non-Small-Cell Lung Cancer

Concomitant Treatment of Brain Metastasis from Non-Small Cell Lung Cancer with Whole Brain Radiotherapy and Gefitinib